| Identification | Back Directory | [Name]
4-P-PDOT | [CAS]
134865-74-0 | [Synonyms]
AH-024
4-P-PDOT
4-PHENYL-2-PROPIONAMIDOTETRALIN
N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
N-(4-Phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propionamide
Propanamide, N-(1,2,3,4-tetrahydro-4-phenyl-2-naphthalenyl)-
4-P-PDOT; 4PPDOT; 4P-PDOT; AH-024; 4-PHENYL-2- PROPIONAMIDOTETRALIN. | [Molecular Formula]
C19H21NO | [MDL Number]
MFCD00901545 | [MOL File]
134865-74-0.mol | [Molecular Weight]
279.38 |
| Chemical Properties | Back Directory | [Melting point ]
166 °C | [Boiling point ]
480.1±45.0 °C(Predicted) | [density ]
1.11±0.1 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
Soluble in DMSO > 10 mM | [form ]
powder | [pka]
15.87±0.40(Predicted) | [color ]
white to beige | [InChI]
1S/C19H21NO/c1-2-19(21)20-16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,2,12-13H2,1H3,(H,20,21) | [InChIKey]
RCYLUNPFECYGDW-UHFFFAOYSA-N | [SMILES]
N(C1CC(c3c(cccc3)C1)c2ccccc2)C(=O)CC |
| Safety Data | Back Directory | [WGK Germany ]
WGK 3 | [RTECS ]
TX1498350 | [HS Code ]
2924.29.7790 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral |
| Hazard Information | Back Directory | [Uses]
4-P-PDOT is a MT2 melatonin receptor ligand. | [Definition]
ChEBI: N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide is a member of tetralins. | [Biological Activity]
Melatonin receptor antagonist, >300-fold selective for the MT 2 (vs MT 1 ) subtype. | [Biochem/physiol Actions]
4-P-PDOT is a slelctive MT2 melatonin receptor antagonist 300 fold selective for MT2 (MEL-1B-R) vs MT1 (MEL-1A-R) melatonin receptor subtype. | [in vivo]
4-P-PDOT (0.5-1.0 mg/kg; intravenous injection; klotho mutant mice) treatment significantly reverses antioxidant effects mediated by Melatonin. And significantly reverses the changes in the levels of these GSH-related parameters. 4-P-PDOT treatment significantly reverses the memory function of Melatonin-treated klotho mutant mice. 4-P-PDOT also counteracts Melatonin-mediated attenuation in response to the decreases in phospho-ERK expression, Nrf2 nuclear translocation, Nrf2 DNA-binding activity, and GCL mRNA expression in the hippocampi of klotho mutant mice[2]. | Animal Model: | Klotho mutant mice treatment with Melatonin[2] | | Dosage: | 0.5 mg/kg or 1.0 mg/kg | | Administration: | Intravenous injection | | Result: | Significantly reversed antioxidant effects mediated by Melatonin. Significantly reversed the changes in the levels of these GSH-related parameters. Significantly reversed the memory function of Melatonin-treated klotho mutant mice.
|
| [IC 50]
MT2 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|